Match!
James G. Zangrilli
AstraZeneca
ImmunologyAsthmaEosinophilBenralizumabMedicine
79Publications
21H-index
2,028Citations
What is this?
Publications 88
Newest
#1Dj Jackson ('KCL': King's College London)
#2Stephanie KornH-Index: 23
Last. James G. Zangrilli (AstraZeneca)H-Index: 21
view all 7 authors...
Eosinophils play a pivotal role in the inflammatory pathology of asthma and have been the target of new biologic treatments for patients with eosinophilic asthma. Given the central role of interleukin (IL)-5 in the eosinophil lifecycle, several therapies directed against the IL-5 pathway have been developed, including the anti-IL-5 antibodies mepolizumab and reslizumab and the IL-5 receptor alpha (IL-5Ralpha)-directed cytolytic antibody benralizumab. Eosinophil-depleting therapies represent a re...
Source
#1G. Walter CanonicaH-Index: 25
#1G. Walter Canonica (Humanitas University)H-Index: 5
Last. George ChristoffH-Index: 1
view all 46 authors...
Summary Regional and/or national severe asthma registries provide valuable country-specific information. However, they are often limited in scope within the broader definitions of severe asthma, have insufficient statistical power to answer many research questions, lack intra-operability to share lessons learned, and have fundamental differences in data collected, making cross comparisons difficult. What is missing is a worldwide registry which brings all severe asthma data together in a cohesiv...
1 CitationsSource
#1Wang Eileen (University of Colorado Hospital)H-Index: 1
#1Wang Eileen (University of Colorado Hospital)
Last. David Price (Aberd.: University of Aberdeen)H-Index: 124
view all 26 authors...
Abstract Background To date, clinical characteristics of the international severe asthma population are unknown. Inter-country comparisons are hindered by variable data collection within regional/national severe asthma registries. Our aim was to describe demographic and clinical characteristics of patients managed in severe asthma services in the USA, Europe, and Asia/Pacific region. Methods The International Severe Asthma Registry (ISAR) retrospectively and prospectively collected data on sever...
2 CitationsSource
#1Sameer K. Mathur (UW: University of Wisconsin-Madison)H-Index: 22
Last. James G. Zangrilli (AstraZeneca)H-Index: 21
view all 6 authors...
Source
#1Bradley E. ChippsH-Index: 32
#2I Hirsch (AstraZeneca)H-Index: 7
Last. James G. Zangrilli (AstraZeneca)H-Index: 21
view all 5 authors...
Abstract Background Fixed airflow obstruction (FAO) is associated with severe eosinophilic asthma. Benralizumab is an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody for patients with severe, uncontrolled eosinophilic asthma. Objective We evaluated FAO influence on benralizumab treatment response. Methods We performed a post hoc analysis of pooled phase III SIROCCO ( NCT01928771 ) and CALIMA ( NCT01914757 ) data for patients with severe, uncontrolled asthma with baseline bloo...
1 CitationsSource
#1G. Walter Canonica (Humanitas University)H-Index: 5
#2M Alacqua (AstraZeneca)H-Index: 10
Last. George ChristoffH-Index: 1
view all 46 authors...
Summary Regional and/or national severe asthma registries provide valuable country-specific information. However, they are often limited in scope within the broader definitions of severe asthma, have insufficient statistical power to answer many research questions, lack intra-operability to share lessons learned, and have fundamental differences in data collected, making cross comparisons difficult. What is missing is a worldwide registry which brings all severe asthma data together in a cohesiv...
Source
#1G. Walter Canonica (Humanitas University)H-Index: 5
#2M Alacqua (AstraZeneca)H-Index: 10
Last. George ChristoffH-Index: 1
view all 46 authors...
Summary Regional and/or national severe asthma registries provide valuable country-specific information. However, they are often limited in scope within the broader definitions of severe asthma, have insufficient statistical power to answer many research questions, lack intra-operability to share lessons learned, and have fundamental differences in data collected, making cross comparisons difficult. What is missing is a worldwide registry which brings all severe asthma data together in a cohesiv...
Source
#1G. Walter Canonica (Humanitas University)H-Index: 5
#2M Alacqua (AstraZeneca)H-Index: 10
Last. George ChristoffH-Index: 1
view all 46 authors...
Summary Regional and/or national severe asthma registries provide valuable country-specific information. However, they are often limited in scope within the broader definitions of severe asthma, have insufficient statistical power to answer many research questions, lack intra-operability to share lessons learned, and have fundamental differences in data collected, making cross comparisons difficult. What is missing is a worldwide registry which brings all severe asthma data together in a cohesiv...
Source
#1G. Walter CanonicaH-Index: 25
#1G. Walter Canonica (Humanitas University)H-Index: 5
Last. David Price (Aberd.: University of Aberdeen)H-Index: 124
view all 46 authors...
Summary Regional and/or national severe asthma registries provide valuable country-specific information. However, they are often limited in scope within the broader definitions of severe asthma, have insufficient statistical power to answer many research questions, lack intra-operability to share lessons learned, and have fundamental differences in data collected, making cross comparisons difficult. What is missing is a worldwide registry which brings all severe asthma data together in a cohesiv...
Source
#1G. Walter CanonicaH-Index: 25
#2M AlacquaH-Index: 10
Last. David PriceH-Index: 124
view all 46 authors...
Source
123456789